GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » Tax Expense

Immunomedics (Immunomedics) Tax Expense : $0.00 Mil (TTM As of Jun. 2020)


View and export this data going back to 1990. Start your Free Trial

What is Immunomedics Tax Expense?

Immunomedics's tax expense for the months ended in Jun. 2020 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2020 was $0.00 Mil.


Immunomedics Tax Expense Historical Data

The historical data trend for Immunomedics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunomedics Tax Expense Chart

Immunomedics Annual Data
Trend Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Dec19
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 -5.05 0.02 0.16 -

Immunomedics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunomedics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunomedics  (NAS:IMMU) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Immunomedics Tax Expense Related Terms

Thank you for viewing the detailed overview of Immunomedics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunomedics (Immunomedics) Business Description

Traded in Other Exchanges
N/A
Address
300 The American Road, Morris Plains, NJ, USA, 07950
Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.
Executives
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt director
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc director, 10 percent owner, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh director, 10 percent owner, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian director, officer: President and CEO 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews officer: Chief Human Resources Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg officer: General Counsel 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik officer: Chief Business Officer & CFO 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney officer: Chief Commerical Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri officer: Chief Medical Officer

Immunomedics (Immunomedics) Headlines

From GuruFocus

Immunomedics to Participate in Upcoming Healthcare Conferences

By Marketwired Marketwired 09-02-2020